Effect of eculizumab on clinical and complement parameters in case 7. Treatments, platelet count, plasma SC5b-9 levels, and complement deposition on ADP-activated HMEC-1 (by calculating HMEC-1 area covered by C5b-9 staining in pixel2) after 4-hr incubation with serum (diluted 1:2 in test medium) from case 7 taken during the acute phase before start of eculizumab treatment (pre-Ecu) and in full remission (normal renal and hematologic parameters) after eculizumab (at the adult dose of 1200 mg every 2 and 3 weeks; post-Ecu). Red arrows indicate times of sampling for plasma SC5b-9 and serum-induced ex vivo complement deposits. Green arrow: from this time, the patient was treated with eculizumab every 3 weeks. Data are mean ± SE of 15 fields examined for each sample. The horizontal rectangle shows range of endothelial C5b-9 deposits with control sera (mean ± SE). °P < .001 vs control serum; $P < .001 vs case 7 pre-Ecu.
